Sanofi Genzyme Co-Pay Assistance Program
Understanding your insurance coverage is very important. Our Case Managers are here to help you and your physician better understand your insurance benefits, so you can get access to the treatment you need. Sanofi Genzyme also offers co-pay assistance and charitable access programs for eligible patients. Learn more by clicking here or by calling 1-800-745-4447, Option 3 Monday through Friday, 8:00 AM to 6:00 PM EST A consent form is required for a Case Manager to work with you, your health care providers and insurance company. This service is offered at no cost to you and is completely voluntary. Any information you provide will be maintained as confidential by Sanofi Genzyme.
The Sanofi Genzyme Co-Pay Assistance Program helps individual in the Unites States pay for their eligible out-of-pocket costs for Cerdelga, including co-pays, co-insurance and deductibles, regardless of financial status*. The program is open to individuals who:
To participate in this program you must complete an enrollment application. Once enrolled, Sanofi Genzyme will cover 100% of your eligible out-of-pocket Cerdelga drug costs up to the program maximum.
Download your application online today! or to learn more about the program call 1-800-745-4447, option 3
Regardless of financial status, the program is open to individuals who:
Have coverage or prescriptions paid for in part or full under any state or federally funded healthcare program including:
Helpful information to have on hand when you apply:
Your application will be reviewed for eligibility.
If you are eligible, you will be automatically enrolled in the program. Enrollment in the program is subject to confirmation of eligibility.
Once approved, you will receive confirmation letter and an enrollment card within 7-10 days. Contact your Case Manager if you do not receive this confirmation. Your doctor or specialty pharmacy will also receive a phone call with instructions on how to submit claims for reimbursement through the program.
Your enrollment in the program is effective from the date of approval through the end of the calendar year (calendar year is January 1 through December 31).
If you are currently enrolled in our Co-Pay Assistance Program you will be automatically enrolled in the program for the next calendar year (January 1 through December 31) unless you decide to opt out of the program or your insurance coverage changes and you are no longer eligible for the program.
* The Co-Pay Assistance Program is available only in the United States. This program assists patients with their out-of-pocket drug costs for their prescribed Sanofi Genzyme treatment only and does not cover or provide support for the cost of MD office visits/evaluations, nursing services/observation periods, blood work, x-rays or other testing, pre-medications/other medications, Epi pens, transportation or other related services. Sanofi Genzyme reserves the right to make eligibility decisions, set program maximums, and rescind, revoke, or amend this program without notice.
The Charitable Access Program (CAP) has been established in the United States through the Sanofi Genzyme Charitable Foundation, Inc. The program is committed to providing Cerdelga to individuals who:
Qualified individuals with Gaucher disease type 1 whose physicians have recommended treatment with Cerdelga may be eligible for the Charitable Access Program. If you are ineligible for our program, your Sanofi Genzyme Case Manager will work with you and your health care providers to explore alternative coverage options.
To be considered for the program, you will be asked to provide the following:
Your Sanofi Genzyme Case Manager will coordinate with you and your patient to obtain the necessary documentation, including a signed waiver, and keep you updated on the status of your patients application.
Applications are reviewed on a monthly basis and are kept confidential by the Charitable Access Program Committee.
Please note that the Charitable Access Program is considered a temporary program. Patients and their families are expected to continue exploring alternative resources with the assistance of a Case Manager. These may include:
To learn more about the Sanofi Genzyme's Charitable Access Program or to request an application form call 1-800-745-4447, Option 3
Disclaimer: The Sanofi Genzyme Charitable Access Program may be discontinued at any time at the discretion of the Charitable Access Program Committee
CERDELGA (eliglustat) capsules is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.
Limitations of Use:
CERDELGA is contraindicated in EMs or IMs taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor, and in IMs or PMs taking a strong CYP3A inhibitor due to the risk of significantly increased eliglustat blood concentration, which may result in prolongation of cardiac intervals that could result in cardiac arrhythmias.
Your doctor will perform a test to help determine if CERDELGA is right for you.
CERDELGA can affect the way other medicines work and other medicines can affect how CERDELGA works. Using CERDELGA with other medicines or herbal supplements (including St. John’s Wort) may cause an increased risk of side effects, including ECG changes and irregular heart beat. Especially tell your doctor if you take medicines for fungal infections, tuberculosis, seizures, heart rhythm and rate problems, high blood pressure, or depression or other mental health problems. Your doctor may need to prescribe a different medicine, change your dose of other medicines, or change your dose of CERDELGA. Tell your doctor about any new medicines before you start taking them.
Before taking CERDELGA, tell your doctor about all of your medical conditions, including kidney or liver problems, history of heart attacks, or heart rhythm problems (including long QT syndrome). If you are pregnant or plan to become pregnant or breastfeed, talk to your physician. It is not known if CERDELGA will harm your unborn baby.
It is not known if CERDELGA is safe and effective in children.
Swallow the capsule whole, preferably with water. If you miss a dose of CERDELGA, take the next dose at the usual time. Do not take two doses of CERDELGA at the same time. Avoid eating or drinking grapefruit products while taking CERDELGA. Grapefruit products can increase the amount of CERDELGA in your body.
The most common adverse reactions (≥10%) for CERDELGA are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain. Call your doctor for medical advice about adverse effects.
You may report adverse effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
If you would like more information, talk with your doctor. You may also go to www.cerdelga.com for the Full Prescribing Information, including the Patient Medication Guide, or call Sanofi Genzyme at 1-800-745-4447.